Key Quantitative Figures

Financial Performance (Quarter Ended June 30, 2026)

  • Revenue from Operations: ₹1,596.32 lakh (unaudited)
  • Other Income: ₹5.22 lakh (unaudited)
  • Total Income: ₹1,601.54 lakh (unaudited)
  • Total Expenses: ₹1,562.35 lakh (unaudited)
  • Profit Before Tax: ₹39.19 lakh (unaudited)
  • Net Profit After Tax: ₹29.78 lakh (unaudited)
  • Total Comprehensive Income: ₹32.12 lakh (unaudited)
  • EPS: ₹2.48 (unaudited)

Comparative Figures

Year-over-Year Comparison (Q1 FY2027 vs Q1 FY2026):

  • Revenue from Operations: ₹1,596.32 lakh vs ₹1,813.54 lakh (decrease)
  • Other Income: ₹5.22 lakh vs ₹18.10 lakh (decrease)
  • Total Income: ₹1,601.54 lakh vs ₹1,831.64 lakh (decrease)
  • Net Profit: ₹29.78 lakh vs ₹96.76 lakh (69.2% decrease)
  • EPS: ₹2.48 vs ₹8.06 (decrease)

Sequential Comparison (Q1 FY2027 vs Q4 FY2026):

  • Revenue from Operations: ₹1,596.32 lakh vs ₹2,044.24 lakh (decrease)
  • Other Income: ₹5.22 lakh vs ₹67.09 lakh (decrease)
  • Net Profit: ₹29.78 lakh vs ₹122.54 lakh (75.7% decrease)
  • EPS: ₹2.48 vs ₹10.21 (decrease)

Expense Breakdown (Q1 FY2027)

  • Cost of materials consumed: ₹579.14 lakh
  • Purchase of Traded Goods: ₹65.01 lakh
  • Changes in inventories: (₹34.83) lakh
  • Employee benefits expense: ₹323.64 lakh
  • Finance Costs: ₹12.30 lakh
  • Depreciation and Amortization: ₹72.90 lakh
  • Other Expenses: ₹444.19 lakh

Other Comprehensive Income

  • Items that will not be reclassified to profit or loss: ₹3.12 lakh
  • Income tax relating to these items: ₹0.78 lakh
  • Total other comprehensive income (net of tax): ₹2.34 lakh

Dates of Action

  • Board Meeting Date: July 25, 2026 (9:30 AM to 11:33 AM IST)
  • Quarter Ended: June 30, 2026
  • Filing Date: July 25, 2026
  • Auditor Review Date: July 25, 2026

Parties Involved

  • Stock Exchange: BSE Limited (Scrip Code: 538964)
  • Statutory Auditors: Naresh & Co. (FRN: 106928W)

Business Segment Information

  • The company operates under a single segment: "Pharmaceuticals Products"

Audit and Review Information

  • Financial results were reviewed and recommended by the Audit Committee
  • Approved by the Board of Directors on July 25, 2026
  • Statutory auditors performed a 'Limited Review' of the financial results
  • Auditors issued an unqualified limited review report confirming no material misstatements

Additional Information

  • Previous quarter's figures have been regrouped/reclassified where necessary
  • Figures for quarter ended March 31, 2026 are balancing figures between audited annual figures and unaudited quarterly figures
  • Paid-up equity share capital: ₹120.00 lakh
  • Other Equity: ₹5,687.65 lakh (as of March 31, 2026)